Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Open access
Fröbert, Ole, Götberg, Matthias, Erlinge, David, Akhtar, Zubair, Christiansen, Evald H., MacIntyre, Chandini R., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Moer, Rasmus, Hlinomaz, Ota, Jakobsen, Lars, Engstrøm, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E, Angerås, Oskar, Calais, Fredrik, Kåregren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Stalby, Per, Islam, Abu K.M.M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., Pernow, John · 2021 · Circulation

Abstract

Background: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. Results: Because of the COVID-19 pandemic, the data safety and monitoring board recommended to halt the trial before attaining the prespecified sample size. Between October 1, 2016, and March 1, 2020, 2571 participants were randomized at 30 centers across 8 countries. Participants assigned to influenza vaccine totaled 1290 and individuals assigned to placebo equaled 1281; of these, 2532 received the study treatment (1272 influenza vaccine and 1260 placebo) and were included in the modified intention to treat analysis. Over the 12-month follow-up, the primary outcome occurred in 67 participants (5.3%) assigned influenza vaccine and 91 participants (7.2%) assigned placebo (hazard ratio, 0.72 [95% CI, 0.52–0.99]; P =0.040). Rates of all-cause death were 2.9% and 4.9% (hazard ratio, 0.59 [95% CI, 0.39–0.89]; P =0.010), rates of cardiovascular death were 2.7% and 4.5%, (hazard ratio, 0.59 [95% CI, 0.39–0.90]; P =0.014), and rates of MI were 2.0% and 2.4% (hazard ratio, 0.86 [95% CI, 0.50–1.46]; P =0.57) in the influenza vaccine and placebo groups, respectively. Conclusions: Influenza vaccination early after an MI or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis, and a lower risk of all-cause death and cardiovascular death, as well, at 12 months compared with placebo. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02831608.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.121.057042

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 272

Metadata

Authors
Fröbert, O., Götberg, M., Erlinge, D., Akhtar, Z., Christiansen, E. H., MacIntyre, C. R., Oldroyd, K. G., Motovska, Z., Erglis, A., Moer, R., Hlinomaz, O., Jakobsen, L., Engstrøm, T., Jensen, L. O., Fallesen, C. O., Jensen, S. E., Angerås, O., Calais, F., Kåregren, A., Lauermann, J., Mokhtari, A., Nilsson, J., Persson, J., Stalby, P., Islam, A. K. M. M., Rahman, A., Malik, F., Choudhury, S., Collier, T., Pocock, S. J., & Pernow, J.
Venue
Circulation
Published
2021-11-02
Volume
144
Issue
18
Pages
1476-1484
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3197803928
Cited by
272
References
27
FWCI
25.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. https://app.cochat.ai/papers/10.1161/circulationaha.121.057042
The paper
Fröbert, O., Götberg, M., Erlinge, D., Akhtar, Z., Christiansen, E. H., MacIntyre, C. R., Oldroyd, K. G., Motovska, Z., Erglis, A., Moer, R., Hlinomaz, O., Jakobsen, L., Engstrøm, T., Jensen, L. O., Fallesen, C. O., Jensen, S. E., Angerås, O., Calais, F., Kåregren, A., . . . Pernow, J. (2021). Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. https://doi.org/10.1161/circulationaha.121.057042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.